-
Journal of the Royal Society of Medicine Dec 1980
Topics: Arthritis, Rheumatoid; Dermatomyositis; Female; Humans; Middle Aged; Penicillamine
PubMed: 7452649
DOI: 10.1177/014107688007301213 -
Physical Chemistry Chemical Physics :... Oct 2021The investigation of the structural characteristics of chiral drugs in physiological environments is a challenging research topic, which may lead to a better...
The investigation of the structural characteristics of chiral drugs in physiological environments is a challenging research topic, which may lead to a better understanding of how the drugs work. Raman optical activity (ROA) spectroscopy in combination with density functional theory (DFT) calculations was exploited to inspect the structural changes in penicillamine under different acid-base states in aqueous solutions. The B3LYP/aug-cc-PVDZ method was employed and the implicit solvation model density (SMD) was considered for describing the solvation effect in HO. The conformations of penicillamine varied with pH, but penicillamine was liable to stabilize in the form of the P conformation (the sulfur atom is in a orientation with respect to carboxylate) in most cases for both D- and L-isomers. The relationship between the conformations of penicillamine and the ROA peaks, as well as peak assignments, were comprehensively studied and elucidated. In the fingerprint region, two ROA couplets and one ROA triplet with different patterns were recognized. The intensity, sign and frequency of the corresponding peaks also changed with varying pH. Deuteration was carried out to identify the vibrational modes, and the ROA peaks of the deuterated amino group in particular are sensitive to change in the ambient environment. The results are expected not only to serve as a reference for the interpretation of the ROA spectra of penicillamine and other chiral drugs with analogous structures but also to evaluate the structural changes of chiral molecules in physiological environments, which will form the basis of further exploration of the effects of structural characteristics on the pharmacological and toxicological properties of chiral drugs.
Topics: Density Functional Theory; Hydrogen-Ion Concentration; Molecular Conformation; Penicillamine; Spectrum Analysis, Raman; Stereoisomerism
PubMed: 34580687
DOI: 10.1039/d1cp02219a -
Postgraduate Medical Journal Aug 1974
Topics: Child; Female; Humans; Keloid; Male; Penicillamine; Scleroderma, Localized
PubMed: 4467176
DOI: No ID Found -
International Immunopharmacology Jul 2020We have previously reported the development of a novel chemical compound, S-Nitroso-N-Pivaloyl-D-Penicillamine (SNPiP), for the upregulation of the non-neuronal cardiac...
S-Nitroso-N-Pivaloyl-D-Penicillamine, a novel non-neuronal ACh system activator, modulates cardiac diastolic function to increase cardiac performance under pathophysiological conditions.
We have previously reported the development of a novel chemical compound, S-Nitroso-N-Pivaloyl-D-Penicillamine (SNPiP), for the upregulation of the non-neuronal cardiac cholinergic system (NNCCS), a cardiac acetylcholine (ACh) synthesis system, which is different from the vagus nerve releasing of ACh as a neurotransmitter. However, it remains unclear how SNPiP could influence cardiac function positively, and whether SNPiP could improve cardiac function under various pathological conditions. SNPiP-injected control mice demonstrated a gradual upregulation in diastolic function without changes in heart rate. In contrast to some parameters in cardiac function that were influenced by SNPiP 24 h or 48 h after a single intraperitoneal (IP) injection, 72 h later, end-systolic pressure, cardiac output, end-diastolic volume, stroke volume, and ejection fraction increased. IP SNPiP injection also improved impaired cardiac function, which is a characteristic feature of the db/db heart, in a delayed fashion, including diastolic and systolic function, following either several consecutive injections or a single injection. SNPiP, a novel NNCCS activator, could be applied as a therapeutic agent for the upregulation of NNCCS and as a unique tool for modulating cardiac function via improvement in diastolic function.
Topics: Animals; Blood Pressure; Cardiovascular Diseases; Heart; Injections, Intraperitoneal; Injections, Intravenous; Mice; Mice, Inbred Strains; Nitric Oxide Donors; Non-Neuronal Cholinergic System; Penicillamine; Ventricular Function, Left
PubMed: 32325404
DOI: 10.1016/j.intimp.2020.106459 -
Scandinavian Journal of Rheumatology.... 1979
Topics: Aldehydes; Arthritis, Rheumatoid; Chemical Phenomena; Chemistry; Chromatography, Gel; Collagen; Humans; Oxidation-Reduction; Penicillamine
PubMed: 287189
DOI: 10.3109/03009747909108229 -
Australian Family Physician Dec 1983Penicillamine is a slow acting oral antirheumatic drug and a chelating agent. Although it is derived from penicillin, allergy to that is not an absolute contraindication...
Penicillamine is a slow acting oral antirheumatic drug and a chelating agent. Although it is derived from penicillin, allergy to that is not an absolute contraindication to the use of penicillamine.
Topics: Arthritis, Rheumatoid; Gold; Humans; Penicillamine
PubMed: 6670953
DOI: No ID Found -
Annals of Internal Medicine Dec 1978
Topics: Adult; Arthritis, Rheumatoid; Female; Humans; Lupus Erythematosus, Systemic; Penicillamine; Syndrome
PubMed: 717982
DOI: 10.7326/0003-4819-89-6-1012_1 -
Lancet (London, England) Mar 1973
Topics: Arthritis, Rheumatoid; Humans; Penicillamine
PubMed: 4120661
DOI: 10.1016/s0140-6736(73)90743-5 -
The Medical Letter on Drugs and... Aug 1978
Clinical Trial
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Penicillamine; Placebos
PubMed: 355819
DOI: No ID Found -
Drug and Therapeutics Bulletin Sep 1974
Topics: Humans; Penicillamine; Scleroderma, Systemic
PubMed: 4469492
DOI: No ID Found